I
nfusion of autoantigenic proteins has been used as a highly efficient therapy to suppress the unfolding of organ-specific autoimmune diseases. The rationale behind this treatment is the observation that soluble autoantigen, when given parenterally at a high dose, inactivates specifically autoimmune effector lymphocytes. Initial trials using candidate autoantigenic proteins in human disease have been disappointing, supposedly because of the unknown nature of the target autoantigen causing the disease (1) (2) (3) . In contrast, application of altered peptide ligands, analogs to autoimmune epitopes, seemed more promising. Such treatment turned out to be beneficial in a substantial proportion of patients. Yet, some of treated individuals developed paradoxical immune responses, including exacerbations of CNS inflammation (4, 5) . The site of altered peptide ligand action, peripheral immune system or CNS lesion, remains largely undetermined. This fact led us to reinvestigate the direct effect of soluble autoantigen on inflammatory autoimmune foci in experimental autoimmune encephalomyelitis (EAE), a classical model reflecting inflammation in human multiple sclerosis (MS) .
Numerous studies have demonstrated that such treatment acts on self-reactive T cells predominantly in the peripheral immune tissues. The infused autoantigen is taken up by peripheral antigenpresenting cells (APCs), which present these autoantigens to specific T cells and drive them into activation and eventually into activation-induced cell death (AICD) (6, 7) . These processes are very efficient and take place at exceptionally high speed. We have studied the effect of i.v. infusion of encephalitogenic proteins (myelin basic protein, MBP) on developing EAE by using encephalitogenic CD4 ϩ T cells genetically labeled to express GFP (8) . We found that within 10 min after protein injection, the effector T cells become arrested around APCs in the lymphoid tissues. These T cells are stimulated to express activation-dependent proinflammatory cytokines, chemokines, and activation markers on their membranes before they undergo activation-induced cell death. As a result, peripheral lymphoid tissues and circulating blood are depleted of autoimmune effector T cells, a process which, obviously, protects against the unfolding of clinical and histological EAE (8) .
The present investigation is focused on the effect of high doses of soluble antigen on the early autoimmune response in the target organ, the CNS. We infused encephalitogenic autoantigens 4-5 days after transfer of encephalitogenic T cells, the critical period of incipient autoimmune inflammation. We found that, much in contrast to prophylactic treatment, soluble autoantigen not only fails to protect from EAE but also enhances the autoimmune attack. The effector cells, which infiltrated the CNS, were arrested around putative APCs and activated to produce large doses of proinflammatory mediators. Interestingly, brain nonspecific ovalbumin-reactive effector/memory T cells, which accumulated within the CNS during autoimmune inflammation, were similarly activated within the CNS parenchyma after i.v. ovalbumin (OVA) infusion and aggravated CNS inflammation and disease severity.
Results
Pathogenic Effects of Antigen Infusion. We induced EAE in healthy syngeneic Lewis rats by transferring 5 ϫ 10 6 activated MBP-specific, GFP-transduced T cell lines (T MBP-GFP cells) (9) . The disease was monophasic with ascending paralysis and weight loss starting 3 days after T cell transfer (p.t.), peaking on day 4, and resolving on day 8 p.t., without later relapses ( Fig. 1 A and B) . As reported before, i.v. infusion of single doses of 500 g of soluble MBP early before onset of EAE (days 1, 2, and 3 p.t.) completely prevented disease induction by instantaneously immobilizing the autoaggressive effector T cells in peripheral immune organs and driving them into activation-induced cell death (8) .
We then infused soluble MBP later, during freshly established clinical EAE (days 4 or 5 p.t.), a stage when the majority of autoaggressive T cells have left the peripheral immune organs through the bloodstream and invaded the CNS parenchyma [supporting information (SI) Fig. 7A ] (10). Instead of preventing EAE development, late i.v. MBP infusion resulted in significant aggravation of clinical disease ( Fig. 1 A and B and SI Table 1 ). In the lesions, we observed strong up-regulation of key proinflammatory cytokines (IFN-␥, IL-17, IL-2, IL-2R, and TNF␣) and chemokines (CXCL9, -10, -11, and CCL5), as demonstrated by quantitative PCR of snap-frozen spinal cords 24 h after i.v. MBP infusion (SI Fig. 7B ). Remarkably, the inflammatory flare went along with a strong increase of nonspecific, recruited inflammatory cells (T and B cells, macrophages) (Fig. 1C) , whereas, in contrast, the numbers of specific effector T MBP-GFP cells remained constant (SI Fig. 8A ). Later, beginning 24 h after i.v. MBP treatment, we observed a clear diminution of effector cells, which paralleled an increase of annexin-V ϩ (pre-) apoptotic T MBP-GFP cells (SI Fig. 8 A and B) . This increase of apoptotic cells was, however, similar between control antigen-and MBP-treated animals (SI Fig. 8B ).
Effector T Cell Motility in the CNS After i.v. Antigen. Previous studies have shown that autoaggressive T MBP-GFP cells freshly arrived in acute EAE lesions meander through the tissue in a stop-and-go mode, with episodes of fast locomotion interchanging with phases of slower migration or brief halts. Some of these T cells ultimately become tethered to particular anchoring points, forming synapse-like contacts to MHC class II ϩ cells and suggesting an antigen-recognition process (11) .
Intravenous infusion of MBP profoundly altered the behavior of T MBP-GFP cells. Intravital two-photon imaging of T MBP-GFP cells of lumbar spinal cord infiltrates documented that, beginning 1 h after i.v. MBP application, the majority of the cells discontinued their trip through the CNS parenchyma: They slowed down and became arrested, tethered at one cell pole ( Fig. 2 and SI Movies 1 and 2). These contact points remained stable for the entire observation period of Ͼ3 h ( Fig. 2 and SI Movies 1 and 2). Infusion of a control antigen, OVA, did not influence the locomotion of T MBP-GFP cells ( Fig. 2 and SI Movies 3 and 4) . In a first attempt to identify the cellular interaction partners of T MBP-GFP cells within the lesion, we intrathecally injected tetramethylrhodamine-dextran, a fluorochrome that labels meningeal and perivascular phagocytes. The majority of arrested T MBP-GFP cells were found in close contact with tetramethylrhodamine-positive cells (SI Fig. 9 A-D and SI Movies 5-7).
In our present studies, intravital imaging allowed a maximal penetration depth of 80 m, covering the meningeal areas and the submeningeal parenchyma. To extend imaging throughout the cross-section of the spinal cord, we analyzed ''acute'' slice explants of infiltrated spinal cords 0, 1, 2, and 3.5 h after MBP infusion (SI Fig. 9E and SI Movies 8 and 9). The treatment affected T MBP-GFP cells throughout the entire spinal cord cross-section including the gray and white matter, again starting Ϸ1 h after i.v. MBP, and reaching a peak value of more than 80% two hours later (SI Fig. 9E ; SI Movies 8 and 9).
Although, as expected, OVA infusion did not change the locomotion behavior of T MBP-GFP cells within the CNS parenchyma ( Fig. 2 and SI Fig. 9A , and SI Movies 10 and 11), this treatment impacted strongly on OVA-specific CD4 ϩ T cells introduced into the CNS. We used a protocol allowing the redirection of GFPlabeled, OVA-specific T cells (T OVA-GFP cells) into the spinal cord and then tested the effect of the specific antigen, OVA, in this milieu. T OVA-GFP cells cotransferred with encephalitogenic T MBP cells are readily recruited into EAE lesions reaching frequencies comparable to the ones of the pathogenic T cell population (SI Fig.  10B ) (11, 12) . They traveled through the spinal cord tissue like their encephalitogenic T MBP-GFP cell counterparts. However, in contrast to the autoaggressive T MBP-GFP cells, the vast majority of T OVA-GFP cells (85-90%) remained constantly in motion, only rarely forming persistent contacts with local CNS cells (11) . Infusion of 500 g of soluble OVA at day 4 p.t. radically changed the behavior of the T OVA-GFP cells. Within 4 h after i.v. OVA infusion, Ͼ80% of Table 2 ).
Uptake and Presentation of Exogenous Antigen by APCs Within the
CNS. In peripheral immune organs, i.v. infused protein antigen is taken up, processed, and presented by APCs in the context of MHC class II molecules as early as 10-15 min after infusion (8, 13) . Recognition of the antigen by T cells and activation follow immediately thereafter (8) . In the CNS, which is secluded from blood circulation by the tight endothelial blood-brain barrier (BBB), and which lacks professional APCs, presentation of soluble antigen may follow distinct schedules.
We traced presentation and processing of OVA within spinal cord lesions using DQ-OVA (Molecular Probes), a fluorochromelabeled, autoquenched substitute of OVA that is inert as intact molecule but becomes fluorescent upon proteolytic digestion. After i.v. infusion, DQ-OVA ϩ cells could not be detected in the noninflamed control CNS parenchyma, presumably because of a denied passage through the BBB (Fig. 4A) . In contrast, during acute EAE (4 days p.t.) the compound was taken up and processed within 30 min by substantial numbers of CNS cells (Fig. 4A and SI Table 3 ). The fluorochrome uptake occurred preferentially in meningeal areas and in the vicinity of vessels, which represent areas mainly affected by the inflammatory infiltrates (Fig. 4A) .
Ex vivo analysis by cytofluorometry showed that the majority of the fluorescent cells (Ͼ90%) 30 min after i.v. DQ-OVA infusion expressed high levels of CD45, identifying them as recruited hematogenic rather than resident cells (SI Table 3 ). However, 1.5 h later, the percentage of DQ-OVA ϩ CD45 low cells increased (Ϸ30%), indicating proteolytic digestion of the tracer by brainresident cells as well. About 35-50% of the DQ-OVA ϩ cells were MHC class II ϩ (SI Table 3 ). The population was composed of monocytes/macrophages, microglial cells (CD11b ϩ and ED2 ϩ ), and B cells (OX-33 ϩ ) (SI Table 3 ). To examine the antigen-presenting potential of phagocytes in EAE lesions, we isolated APCs from EAE spinal cords 2 h after i.v. infusion of OVA or saline by using gradient centrifugation (14) . The cells were irradiated and cultured together with T OVA-GFP cells as ovalbumin-specific reporter cells. Quantitative PCR revealed that T OVA cells produced significantly higher amounts of IFN␥ after exposure to APCs isolated from i.v. OVA-treated rats compared with APCs from PBS-treated animals (Fig. 4B ). This effector cell response depended on MHC class II molecules. Addition of blocking anti-class II antibodies (OX-6), but not isotype control or anti-MHC class I (OX-18) antibodies, prevented cytokine mRNA up-regulation (Fig. 4B) .
Effect or Exogenous Antigen on Autoaggressive Effector T Cells in Situ.
We next explored whether increased immobilization of migrant T MBP-GFP cells within EAE lesions after i.v. MBP correlated with T cell activation. Spinal cords were isolated 1, 2, and 4 h after i.v. MBP infusion, and mRNA was prepared from the snap-frozen tissues. Real-time PCR revealed strong elevation of IFN␥, IL-17, IL-2, 
IL-2R
, and TNF␣ beginning as early as 1 h after i.v. MBP ( Fig. 5A and SI Fig. 11 A) . These changes were likely due to up-regulated mRNA expression of the effector T cells, because similar responses were seen in T MBP-GFP cells sorted from spinal cords after i.v. MBP infusion ( Fig. 5A and SI Fig. 11 A) . IFN␥ production was confirmed with intracellular staining of T MBP-GFP cells recovered from the spinal cord 6 h after i.v. MBP. Sixty percent of the T cells produced IFN␥ after i.v. MBP infusion, compared with Ϸ30% of the T cells after i.v. infusion of control antigen (Fig. 5B) . Membrane activation markers (OX-40 antigen and IL-2R) were up-regulated on effector T cells 4 h and 12 h after i.v. MBP, whereas CD3/␣␤TCR complex was partially reduced (SI Fig. 11B ). Similar changes were found in T OVA-GFP cells cotransferred with T MBP cells and treated with i.v. OVA 4 days p.t. (Fig. 5 C and D and SI Fig. 11 C and D) .
Effect of Exogenous Antigen on Brain-Nonspecific Memory T Cells
Recruited to EAE Lesions. Our findings so far indicate that postactivated effector T cells home into acute EAE lesions and can be reactivated locally by exogenous antigen irrespective of the specificity of the intruding T cell population. To test whether this holds true as well for nonbrain antigen-specific resting memory T cells, we induced EAE in adult, 10-to 12-week-old animals harboring GFP-labeled OVA-reactive T cells as a defined memory cell population. T OVA-GFP cells instilled into neonatal animals persist in the secondary lymphoid organs as classical memory T cells lifelong in frequencies of 1 ϫ 10 Ϫ4 to 1 ϫ 10 Ϫ3 (15). In healthy animals, these brain-nonspecific memory T cells were excluded from the CNS tissue (SI Fig. 12A ) (15) . This scenario changed drastically after induction of adoptive transfer EAE by transferring redfluorescent-protein-labeled T MBP cells (T MBP-RFP cells). T OVA-GFP memory cells 96 h after transfer of T MBP-RFP cells accumulated in the inflamed CNS in significant numbers, reaching frequencies up to 10% of the autoaggressive T MBP-RFP cell population (SI Fig.  12 A) . Further, the recruited memory T cells were distributed throughout the CNS parenchyma similarly to T MBP-RFP cells (SI Fig.  12B ). In contrast to the pathogenic T cells, however, the T OVA-GFP memory cells did not show any signs of local reactivation, as shown by low expression of surface activation markers OX-40 and IL-2R (Fig. 6A) . Infusion of i.v. OVA, however, led to strong activation of the T OVA-GFP memory cells within the CNS, as reflected by up-regulation of IL-2R and OX-40 antigen and the production of IFN␥ (Fig. 6 A and B) . This activation of memory T cells within the CNS was accompanied by increased local inflammation, as shown by elevated proinflammatory cytokine mRNA (Fig. 6C ) and moderate, but significant, aggravation of clinical signs (SI Table 4 ).
Discussion
Organ-specific autoimmune diseases are caused by T lymphocytes reactive against specific autoantigens that are presented within the target tissue. Initially, the pathogenic T cells are activated outside the target organ and reach their destination after a complex, but well ordered, migratory route. In the case of T cell-transferred EAE, in vitro activated encephalitogenic T cells migrate through a sequence of lymphoid organs before they pass through the BBB and enter their CNS target tissue. During their migration, the effector cells undergo a profound remodeling of their gene expression profile, which in the end renders them fit for the organ retrieval and invasion (10) .
In a previous study, we examined the well known protective effect of soluble autoantigen infused in the early phase of autoimmune response, the period spanning between T cell transfer and onset of clinical disease (8) . At this stage, most effector T cells accumulate in the spleen, forming transient contacts with local stromal cells. We described that infused autoantigen instantaneously arrests the motile T cells and drives them into activation, and ultimately into activation-induced cell death. Consequently, early autoantigen treatment results in complete prevention of clinical autoimmune disease (8) .
This article explores the effect of soluble autoantigen in a later phase, when the effector cells have moved from the spleen to the CNS, there forming the pathogenic infiltrates. We found that the infused autoantigen reached the CNS tissue, although in a slightly protracted fashion. The protein is then taken up and processed by local APCs and presented to effector T cells. However, instead of protecting, this late treatment exacerbates autoimmune disease. Increase of local T cell activation and disease aggravation after i.v. antigen was detectable in doses ranging from 0.5 g to 10 g per rat (SI Fig. 13 and SI Table 5 ).
Presentation of exogenous antigen within the CNS was fast, yet it lagged behind presentation within the spleen. This delay was due to the slower entrance of the molecules into the nervous tissue, rather than to protracted antigen processing and presentation. Indeed, lymphoid tissues are connected to permeable blood vessels by specialized conduits (16) , much in contrast to the CNS, which is shielded by a tight BBB (17, 18) . Although in inflammatory areas the neural BBB becomes leaky, this permeability does not seem to be absolute. We noted uptake of circulating macromolecules in perivascular phagocytes starting Ϸ30 min after i.v. injection. However, different sets of CNS phagocytes took up the antigenic marker proteins sequentially, depending on their location within the tissue. The first phagocytes resembled macrophages, either autochthonous perivascular cells or freshly infiltrated. Perivascular bone-marrowderived cells (19, 20) sharing features with dendritic cells (21) likely serve as APCs required to direct circulating effector T cells into the target tissue, and thus to ride the autoimmune attack. After a delay of another 30 min, however, the label was additionally seen in CD45 low cells, most likely microglial cells. The efficiency of antigen processing was assessed by using DQ-OVA, ovalbumin heavily substituted with a quenched dye, which in its native state fails to emit fluorescent light, but after proteolytic cleavage becomes an efficient fluorochrome. DQ-OVA processing in CNS-located phagocytes in situ as in vitro did in no demonstrable way lag behind processing by peripheral APCs (data not shown), indicating that they are fully efficient. Furthermore, processing and presentation of DQ-OVA was functional. OVAspecific T cells redirected into the CNS were activated by DQ-OVA-loaded APCs and contributed to exacerbation of ongoing EAE mediated by MBP-specific T cells. They behaved like OVAspecific T cells that caused EAE-like CNS inflammation after topical instillation of antigen into CNS tissue (22) .
The behavior of autoimmune effector T cells within the CNS parenchyma may be described as stereotypic. Most of these cells roam through the tissue in an apparently undirected, erratic way, often changing direction and velocity. A subset of the cells, however, gets anchored to local cells forming synapse-like contacts to MHC class II ϩ CNS cells, a process suggesting presentation and recognition of (auto-)antigen (11) . Penetration and processing of exogenous MBP immediately impacted on the migratory behavior of T cells. Within 1-2 h, the majority of freely migrant lymphocytes became arrested. This process was followed by substantial T cell activation. Transcription and translation of surface activation markers and proinflammatory cytokines and chemokines were abruptly increased followed by a sharp, but transient, exacerbation of clinical disease.
Increased activation of autoimmune T cells by exogenous autoantigen may be surprising considering that within their natural habitat, CNS APCs are permanently fed with myelin and other local autoantigen. However, apparently, local autoantigen is not available at saturating concentrations. Suboptimal supply of autoantigen in the tissue may be responsible for the relatively low efficiency of naturally loaded APCs to present ex vivo endogenous myelin protein (23) . Thus, in our experiments, exogenous MBP is required to enhance presentation of the autoantigen to invading effector T cells, and consequently to exacerbate disease. The identity of the cells which present the exogenous antigen within the CNS parenchyma, at this point is still not completely clear but most likely includes recruited as well as resident phagocytic cells (Fig. 4A and SI Table 3 ).
Several investigations (24) (25) (26) have tested the effect of soluble autoantigen on established clinical EAE, but they did not report an exacerbating treatment effect. Most importantly, Weishaupt et al. (25) , studying T cell-mediated EAE in Lewis rats, observed a robust and prompt increase of TNF␣ production within the CNS right after infusion of soluble autoantigen, but this response did not translate into clinical exacerbation. Timing of treatment may be responsible for the lack of effect. The full development of CNS autoimmune infiltrates by incoming effector T cells takes a period of Ϸ1 day. Treatment with soluble autoantigen during this build-up phase will act on the one hand on the freshly arrived local T cells and, at the same time will curb ongoing invasion (8) . Thus, activation of T cells may be outbalanced by a blockade of further infiltration.
It is known that at least CD8 ϩ T cell accumulate and persist as clonally expanded populations in MS brains (27, 28) . The specificity of these T cell clones, however, remains to be identified. In our study, memory T cell populations that were directed against a nonbrain antigen (OVA) were recruited to the CNS and dispersed throughout the CNS parenchyma indistinguishably from the pathogenic T cell population. These observations indicate that the clonally expanded T cell populations in MS brains might well represent non-CNS antigen-specific memory cells that have assembled in the immune repertoire in the course of previous infections.
Infections are well known to trigger disease relapses and exacerbations in MS (29) . How they do so is not fully understood. Several scenarios, however, have been proposed. The ''antigenic mimicry'' concept refers to sequence identities between peptides from microbes and autoantigens, which erroneously trigger autoreactive T cells to attack their own body organs (30) . Autoreactive T cells might be further instigated by bacterial superantigens or by antigen-nonspecific proinflammatory factors of the innate immune system, which are abundantly expressed in inflammatory milieus 31, 32) . Weakening of the regulatory system that normally controls autoimmune responses might support these processes (33) . Our data indicate an alternative method by which previous encounters with infectious agents might predispose for subsequent organspecific damage. Memory cells directed against previous aggressors persist within the immune repertoire over decades. These memory cells are readily recruited to inflamed tissues, which seemingly include the often clinically silently inflamed MS brain. Our data suggest that components of pathogens that spread in the circulation during reinfections will reach the inflamed CNS and will be locally presented to specific memory T cells. Depending on their numbers and properties, the resulting reactivation cascade might trigger disease exacerbation.
Collectively, we have shown here that during florid CNS inflammation, exogenous protein antigens readily reach the CNS lesions and are presented there to local infiltrating T lymphocytes. These findings are of significant clinical importance. First, our demonstration that autoimmune effector T cells are activated by exogenously administrated autoantigen and thus cause exacerbation of ongoing disease has therapeutic implications. Treatment of MS with soluble antigen or agonistic analogs may reach CNS lesions and, given appropriate conditions, may cause adverse effects. Second, we noted that ''irrelevant'' CD4 ϩ memory T cell clones that are unspecifically recruited into the CNS by pathogenic effector T cells can be locally reactivated by antigen reaching the CNS through the bloodstream and a perforated BBB. It is tempting to speculate that such ectopic antigen presentation may help to explain the association of MS relapses with ''unspecific'' infections (29) . 
Materials and Methods

CD4
ϩ T MBP-GFP , T OVA-GFP , and T MBP-RFP cells were generated and tested for their phenotype, cytokine profile, and antigen specificity as reported (8, 9) . Adoptive transfer EAE was induced by i.v. injection of 5 ϫ 10 6 T cells. Weight and clinical scores were monitored twice daily. Clinical scores were as follows: 0, no disease; 1, flaccid tail; 2, gait disturbance; 3, complete hind limb paralysis; 4, tetraparesis; 5, death. Memory animals were established by i.p.
transfer of T OVA-GFP cells (2 ϫ 10 6 cells 5 days after stimulation with OVA-pulsed APCs, in 0.5 ml of Eagle's Hepes medium (per animal) into newborns as described (15) . EAE was induced in 3-month-old T OVA-GFP memory animals by passive transfer of 5 ϫ 10 6 T MBP-RFP cell blasts.
Intravital Imaging. Surgical procedure and intravital imaging settings.
Animals were deeply anesthetized as reported by i.p. injection of xylazine/ketamine (10 mg/kg and 50 mg/kg, respectively) (8, 11) . After midline skin incision of 2-3 cm and detachment of the paravertebral musculature laminectomy was performed at the level of Th12/L1 to create spinal imaging window. The dura was left intact. Animals were stabilized in a custom-made microscope stage. Body temperature was controlled by a heated pad (37°C). Stereotactic intrathecal injection of tetramethylrhodamine-dextran (40 g) was performed into the cisterna magna 24 h before induction of EAE. Live imaging. Time-lapse two-photon laser scanning microscopy and fluorescence video microscopy time-lapse recordings were performed as described (11) . Detailed information is provided in SI Materials and Methods.
Cell Isolation, Cytofluorometry, and FACS. Explanted organs were homogenized on ice. Single cell suspensions were prepared as described (8, 10) . T GFP cells were sorted by using FACS Vantage (Becton Dickinson, Heidelberg, Germany). All procedures were performed at 4°C. Cytofluorometric analysis was performed with FACS-Calibur operated by Cell Quest software (Becton Dickinson). Intracellular IFN␥ staining was performed as described (34) . The antibodies used are listed in SI Materials and Methods.
Antigen Presentation of ex Vivo-Isolated CNS Cells After i.v. Antigen
Infusion. APCs were isolated from the CNS of diseased animals as described (14) . The rat had received i.v. OVA or PBS 2 h earlier.
The APCs were irradiated and cocultured with resting T OVA-GFP cells in 96-well plates (in DMEM 1% rat serum). Blocking anti-MHC class II (OX-6), anti-MHC class I (OX-18), or IgG control antibodies were added to the cultures (10 g/ml). Real-time PCR for IFN␥ was performed on the mRNA from the cultures collected after 24 h. 
